Prophylactic biologic use in hereditary angioedema treatment is expanding, and the latest industry analysis names it as the single largest force behind the market's growth over the coming decade. Physicians are moving more patients onto maintenance regimens designed to prevent swelling attacks before they start instead of treating them once they occur, and newer formulations that ease the dosing burden are accelerating that shift. The effect is not evenly spread: it lifts some product categories far faster than the market as a whole.
Contrive Datum Insights has published a new analysis of the global hereditary angioedema market, sizing it at USD 3.75 billion in 2025. The market reaches USD 4.08 billion in 2026 and USD 7.15 billion by 2034, a compound annual growth rate of 7.27% across the forecast period.
Kallikrein Inhibitor therapies absorb most of that prophylactic shift. The category compounds at 10.93% a year, and its share of total revenue rises from 17.6% in 2025 to 24.06% in 2034. In dollar terms it grows from USD 0.66 billion to USD 1.72 billion over the same stretch, more than doubling while the market as a whole does not.
North America carries the largest share of that growth. The region holds 50.21% of 2025 revenue, USD 1.88 billion, and climbs to USD 3.36 billion by 2034. Asia Pacific advances more gradually, its share of global revenue moving from 14.79% to 18% as its market expands from USD 0.56 billion to USD 1.29 billion. Middle East and Africa remains the smallest region throughout the forecast, edging up from 3.36% to only 4% of the total.
None of this growth is guaranteed to hold at the base-case pace. The bear case in the study points to slower diagnosis rates, payers continuing to press on price, and reimbursement approval for newer oral therapies lagging in several markets; under those conditions, 2034 revenue reaches USD 6.08 billion instead of USD 7.15 billion. The numbers already hint at that risk: C1 Esterase Inhibitor still accounts for 62.4% of 2025 revenue, and it grows at just 5.15% a year, well below the market's 7.27% average. A category that large advancing that slowly narrows how far the prophylactic story alone can carry the forecast.
The study segments the market by application, treatment type, route of administration and end user in addition to type, with revenue and growth estimates for every line from 2020 through 2034. It is delivered as a PDF, and a free sample is available on request from Contrive Datum Insights.